Company Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois.
The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome.
It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies.
The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
| Country | United States |
| Founded | 2005 |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 377 |
| CEO | John Shannon |
Contact Details
Address: 180 North LaSalle Street, Suite 1600 Chicago, Illinois 60601 United States | |
| Phone | 844 445 5704 |
| Website | xerispharma.com |
Stock Details
| Ticker Symbol | XERS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001346302 |
| CUSIP Number | 98422E103 |
| ISIN Number | US98422E1038 |
| Employer ID | 20-3352427 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John P. Shannon | Chief Executive Officer and Director |
| Steven M. Pieper | Chief Financial Officer |
| Beth P. Hecht J.D. | Chief Legal Officer and Corporate Secretary |
| Paul R. Edick J.D. | Senior Advisor |
| Dr. Kenneth E. Johnson Pharm. D., Pharm.D. | Senior Vice President of Global Development and Medical Affairs |
| Allison Wey | Senior Vice President of Investor Relations and Corporate Communications |
| Brian Conner | SVice President of Quality and Chief Compliance and Risk Officer |
| Kendal Korte | Senior Vice President of Human Resources |
| Kevin McCulloch | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 15, 2021 | 15-12B | Securities registration termination |
| Oct 6, 2021 | EFFECT | Notice of Effectiveness |
| Oct 5, 2021 | 25-NSE | Filing |
| Oct 5, 2021 | POS AM | Post-Effective amendments for registration statement |
| Oct 5, 2021 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 5, 2021 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 5, 2021 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 5, 2021 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 5, 2021 | 8-K | Current Report |